Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review (Q33377162)

26 July 2017

1 reference

title

Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review (English)

1 reference

systemic lupus erythematosus

26 July 2017

1 reference

1 reference

C C Mok

1

1 reference

26 July 2017

publication date

1 September 2007

1 reference

Scandinavian Journal of Rheumatology

26 July 2017

published in

1 reference

26 July 2017

volume

36

1 reference

26 July 2017

issue

5

1 reference

26 July 2017

page(s)

329-337

1 reference

Mycophenolate mofetil in lupus glomerulonephritis

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate therapy of SLE membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil for lupus related myelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Acute pancreatitis in paediatric systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil: a new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Augmentation of T-cell apoptosis by immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Positive effect on T-cell regulatory apoptosis by mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Effect of mycophenolic acid on TNF alpha-induced expression of cell adhesion molecules in human venous endothelial cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fcgamma receptor III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Modulation of autoantibody production by mycophenolate mofetil: effects on the development of SLE in (NZB x NZW)F1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Immune pathophysiology of autoimmune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil: new applications for this immunosuppressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses production of pro-inflammatory cytokines, nitric oxide, and LDH in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

Mycophenolic acid downregulates inducible nitric oxide synthase induction in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

The immunosuppressant mycophenolate mofetil attenuates neuronal damage after excitotoxic injury in hippocampal slice cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740701607042

10.1080/03009740701607042

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference